<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04620031</url>
  </required_header>
  <id_info>
    <org_study_id>HSK3486-307</org_study_id>
    <nct_id>NCT04620031</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Sedation of Intravenous Administration of HSK3486 Injectable Emulsion in ICU Patients Undergoing Mechanical Ventilation</brief_title>
  <official_title>A Multi-Center, Randomized, Single-Blind, Propofol-Controlled Phase III Clinical Study Evaluating Sedation of Intravenous Administration of HSK3486 Injectable Emulsion in ICU Patients Undergoing Mechanical Ventilation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haisco Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haisco Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, single-blind, propofol-controlled phase III clinical&#xD;
      study. In this study, ICU patients undergoing mechanical ventilation are expected to be&#xD;
      enrolled and will be randomly assigned to the HSK3486 group and the propofol group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 8, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success rate of sedation</measure>
    <time_frame>Within 24 hours of administration</time_frame>
    <description>1) The time period during which the RASS is in the range of +1 to -2 accounts for ≥ 70% of the total duration of study administration and 2) Remedial treatment is not used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean qualified rate of sedation</measure>
    <time_frame>Within 24 hours of administration</time_frame>
    <description>Defined as the percentage of time period during which the RASS is in the range of +1 to -2 relative to the total duration of study administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of study drug</measure>
    <time_frame>Within 24 hours of administration</time_frame>
    <description>the loading doses of HSK3486 and propofol, mean maintenance dose and total dose per unit weight per hour of HSK3486 or propofol, and the number of dose modifications and the number of top up doses during the maintenance period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of remedial drugs per unit weight</measure>
    <time_frame>Within 24 hours of administration</time_frame>
    <description>the mean dose per unit weight per hour of other sedatives used to maintain the target sedation (RASS within +1 to -2 points)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to extubation</measure>
    <time_frame>Within 24 hours after administration</time_frame>
    <description>the time from intubation (applicable to patients who undergoes intubation after entering the ICU)/ICU admission (applicable to patients with intubation before entering the ICU) to extubation or the time from drug discontinuation to extubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recovery</measure>
    <time_frame>Within 24 hours after administration</time_frame>
    <description>the time for the subject to recover from sedation to full recovery of consciousness (RASS ≥ 0) after discontinuation of drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>From day -1 to 24 hours after administration</time_frame>
    <description>safety endpoits</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Sedation in Intensive Care</condition>
  <arm_group>
    <arm_group_label>HSK3486</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK3486</intervention_name>
    <description>Loading Dose：0.1 mg/kg, infused with 4 min ± 30 s； Maintenance Dose：Maintenance is started at 0.3 mg/kg/h, and the dose can be adjusted up and down by 0.05-0.1 mg/kg/h. Range of maintenance dose: 0.06-0.8 mg/kg/h</description>
    <arm_group_label>HSK3486</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Loading Dose：0.5 mg/kg, infused with 4 min ± 30 s&#xD;
Maintenance Dose：Maintenance is started at 1.5 mg/kg/h, and the dose can be adjusted up and down by 0.25-0.5 mg/kg/h. Range of maintenance dose:&#xD;
0.3-4 mg/kg/h</description>
    <arm_group_label>Propofol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who require tracheal intubation for mechanical ventilation are expected to&#xD;
             require 6-24 h of sedation after randomization;&#xD;
&#xD;
          2. The target RASS for the required sedation of patients ranges from +1 to -2 points;&#xD;
&#xD;
          3. Aged ≥ 18 and &lt; 80 years old, with no gender requirement;&#xD;
&#xD;
          4. 18 kg/m2 ≤ BMI ≤ 30 kg/m2;&#xD;
&#xD;
          5. The patients or their family members fully understand the objectives and significance&#xD;
             of this study, and voluntarily participate in this clinical study and sign the&#xD;
             informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients known to be allergic to eggs, soy products, opioids and their antidotes, and&#xD;
             propofol; patient having contraindications to propofol, opioids and their antidotes;&#xD;
&#xD;
          2. Patients who have received sedation for more than 3 days in the ICU or in the general&#xD;
             ward before being transferred to the ICU before signing informed consent form;&#xD;
&#xD;
          3. Patients having the following medical history or evidence of any of the following at&#xD;
             screening, which may increase sedation/anesthesia risk:&#xD;
&#xD;
               1. Cardiovascular system: New York Heart Association (NYHA) Class III and IV heart&#xD;
                  failure, Adams-stokes syndrome; acute coronary syndrome (ACS) that occurs within&#xD;
                  6 months before screening; bradycardia requiring medication and/or heart rate ≤&#xD;
                  50 beats/min; a history of severe arrhythmia such as II-III degree&#xD;
                  atrioventricular block (excluding patients using pacemakers); acute and chronic&#xD;
                  myocarditis; patients who require vasoactive drugs to maintain a normal blood&#xD;
                  pressure;&#xD;
&#xD;
               2. Patients with mental system disorders (such as schizophrenia, depression, etc.)&#xD;
                  and cognitive disorders; patients with a history of abuse of psychotropic drugs&#xD;
                  and anesthetics; patients with a history of alcohol abuse within 3 months prior&#xD;
                  to screening; patients with a history of drug abuse; patients with a history of&#xD;
                  long-term use of psychotropic drugs, etc.;&#xD;
&#xD;
               3. Severe hepatic and renal insufficiency (liver function: refer to child-pugh grade&#xD;
                  C, the scale is shown in Appendix 6; renal function: glomerular filtration rate&#xD;
                  eGFR ≤ 30 mL/(min•1.73 m2) [eGFR is calculated using the Modification of Diet in&#xD;
                  Renal Disease (MDRD) equation: eGFR = 175 × serum creatinine (SCr)-1.234 ×&#xD;
                  age-0.179 × 0.79 (females)]; patients undergoing dialysis;&#xD;
&#xD;
               4. Grand mal epilepsy and convulsion; craniocerebral injury, intracranial&#xD;
                  hypertension, cerebral aneurysm; a Glasgow coma scale (GCS) of ≤ 12 points (see&#xD;
                  Appendix 4 for the scale); a SOFA scale of &gt; 9 points (see Appendix 5 for the&#xD;
                  scale); patients with high paraplegia and general paralysis;&#xD;
&#xD;
               5. Expected survival of ≤ 72 h.&#xD;
&#xD;
          4. Pregnant or lactating females; women or men of child-bearing potential who are&#xD;
             unwilling to use contraception through the study; subjects who are planning pregnancy&#xD;
             within 1 month after the study (including male subjects);&#xD;
&#xD;
          5. Have participated in any other clinical trials within 1 month prior to screening;&#xD;
&#xD;
          6. Other conditions that patients are judged by the investigator to be unsuitable for&#xD;
             participating in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Liu xiao</last_name>
    <phone>15921176768</phone>
    <email>liux1@haisco.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>guan xiangdong</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 21, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

